Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Champions Oncology (NAS:CSBR) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Champions Oncology Forward PE Ratio Related Terms
Champions Oncology Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Forward PE Ratio Chart
Champions Oncology Annual Data
Trend
2020-04
2021-04
2022-04
2023-04
2025-04
Forward PE Ratio
54.95
64.94
30.67
49.26
35.91
Champions Oncology Quarterly Data
2018-07
2018-10
2019-07
2019-10
2020-01
2020-04
2020-07
2020-10
2021-01
2021-04
2021-07
2021-10
2022-01
2022-04
2022-07
2022-10
2023-01
2023-04
2023-07
2024-10
2025-01
2025-04
2025-07
2025-10
2026-01
Forward PE Ratio
217.39
92.59
25.58
40.00
50.51
54.95
87.72
147.06
62.89
64.94
80.65
98.04
36.23
30.67
32.57
47.17
20.53
49.26
68.49
31.35
48.33
35.91
28.36
31.32
74.81
CSBR vs SEER, RLYB, FBIO: Forward PE Ratio Comparison
For the Biotechnology subindustry, Champions Oncology's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Champions Oncology (CSBR) has a Forward PE Ratio of 60.00 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Champions Oncology and its competitors. According to the industry distribution chart, Champions Oncology ranks #279 out of 354 companies in the Biotechnology industry, placing it in the top 78.8%.
Is Champions Oncology's Forward PE Ratio too high?
Champions Oncology's current Forward PE Ratio is 60.00. The Biotechnology industry median Forward PE Ratio is 21.97. Champions Oncology's value of 60.00 is 173.1% above this industry median. Based on the distribution chart, Champions Oncology ranks #279 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Forward PE Ratio compare to SEER and RLYB?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #279 out of 354 companies for Forward PE Ratio. This places Champions Oncology in the lower half of its industry. The industry median Forward PE Ratio is 21.97. Champions Oncology's value of 60.00 is 173.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Forward PE Ratio of 60.00 is 173.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Forward PE Ratio is 60.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.67, compared to a current price of $6.00 — trading 10% below its estimated fair value. The current Forward PE Ratio is 60.00 and 173.1% above the Biotechnology industry median of 21.97. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Forward PE Ratio is 60.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.00 is trading 10% below its estimated GF Value™ of $6.67.
GuruFocus considers Champions Oncology to be Modestly Undervalued.
Key valuation signals for CSBR:
Forward PE Ratio: 60.00
GF Value™: $6.67 vs. price of $6.00 (10% below fair value)
Industry Position: 173.1% above the Biotechnology median (#279 of 354)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
